Our Therapy: OCLX-001 Gene Therapy

While today’s approved treatments only slow late-stage disease, OCLX-001 is designed for patients at the intermediate stage of AMD—before irreversible damage sets in.

• Epigenetic approach: OCLX-001 delivers the BMI1 gene, a master regulator of cellular renewal and protection against oxidative stress.

• Protects photoreceptors: By restoring BMI1 levels in the retina, OCLX-001 helps preserve vision cells that would otherwise be lost.

• One-time treatment: A single injection aims to provide long-lasting protection, reducing the need for frequent injections.

• Broad potential: Our platform may be applied to AMD, diabetic retinopathy, and other degenerative retinal diseases.

Our Proprietary Needle: Precision Suprachoroidal Delivery

Traditional intravitreal injections deliver medicine into the center of the eye, but often with limited reach and frequent repeat procedures. Our OCLX-SCDD needle is engineered to do more:

• Targeted delivery into the suprachoroidal space, reaching the retina and choroid more effectively.

• Minimally invasive design that reduces patient discomfort and injection risk.

• Broad coverage across the back of the eye, maximizing therapeutic impact for retinal and macular diseases.

• Easy to use design allows for injections with one hand.

• Built to clinical standards (FDA and ISO compliant) for safety and reliability.

This innovative device allows us to place gene therapies precisely where they are needed, opening new doors for treating blinding retinal diseases.